

**Vanderbilt Human Research Protection Program  
Radioactive Drug Research Committee – Institutional Review Board  
FDA Registration Number – RDRC013**

The RDRC Committee meets the first Friday of every quarter at 10:00AM. Meeting locations are subject to change. Please call the VHRPP office to confirm meeting location (322-2918).

Effective – August 20, 2020 – July 14, 2021

**VOTING MEMBERS (5)**

Eric Shinohara, MD – Chair	Hematology/Oncology
Gary Smith, MD - Vice-Chair	Nuclear Medicine
Mary Ann Keenan, DMP	Radiology and Radiological Sciences
Marni Gardner, DPh	Nuclear Pharmacy
David Pickens, PhD	Radiology and Radiological Sciences

**ALTERNATE MEMBERS**

Bapsi Chakravarthy, M.D. Radiation Oncology  
Dominique Delbeke, M.D., Ph.D. Nuclear Medicine  
Chirayu Shah, M.D. Nuclear Medicine  
Joe Harper, PharmD, Nuclear Pharmacist

Vanderbilt’s Radioactive Drug Research Committee (RDRC) is authorized by the U.S. Food and Drug Administration (FDA) to approve research projects involving the use of certain “non-approved” radioactive drugs for pre-Phase 1 research which would otherwise require approval from the FDA in the form of an Investigational New Drug (IND). Use the RDRC application form embedded in the IRB application and guidelines to submit proposals to the RDRC. If you need help in completing and RDRC application and/or estimating the radiation dose, contact the IRB to have the Radiation Dose Calculation Member of the RDRC assist you.

For a list of radiation doses, or examples of risk statements, please go to the [Radiation Dose Calculator](#).